A new post hoc 10–year follow–up analysis of the MI–GENES randomized clinical trial has found that disclosing a polygenic risk score (PRS) for coronary heart disease (CHD) may significantly reduce long–term cardiovascular events.
The study followed 203 participants who were originally randomized to receive either a standard Framingham risk score (FRSg) or an integrated risk score (IRSg) that also included a PRS.
The study found that patients who received their polygenic risk score (PRS) experienced 77% fewer major adverse cardiovascular events (MACE) and a 39% reduction in diagnostic testing for coronary heart disease (CHD), compared to those who received only a standard clinical risk score.
These benefits were linked to greater statin use and more significant reductions in LDL cholesterol over the years following risk disclosure. Other health indicators–such as blood pressure, weight, and A1C–did not differ significantly between the groups.
“This is not the future – it’s already here,” said Dr. Eran Feldhay, CEO of OpenDNA. “Studies like MI-GENES confirm what we believe: that personalized, proactive health starts with understanding your genetic risk.”
These results offer important real–world insight into how polygenic risk information may influence preventive behaviors and long–term outcomes.
OpenDNA’s risk assessment platform is designed to bring these insights into routine care, helping clinicians personalize cardiovascular prevention strategies with greater precision.
